Literature DB >> 1642477

Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome.

.   

Abstract

We report the one-year assessment of plasma exchange (PE) versus control in Guillain-Barré syndrome (GBS), based on a randomized multicenter clinical trial of 220 patients with GBS. Treated patients received four PEs, with either albumin or fresh frozen plasma (FFP) as replacement fluid. This study completes the short-term analysis previously published (Ann Neurol 1987;22: 753-761). Long-term benefit from PE was observed, as demonstrated by full muscular strength recovery at one year: 71% in the PE group versus 52% in the control group (p = 0.007), confirmed after adjustment for four prognostic factors. FFP showed no additional benefit compared with albumin (77% full recovery in the FFP group versus 65% in the albumin group; p = 0.22). PE did not affect the incidence of severe motor disability (11% in both groups).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642477     DOI: 10.1002/ana.410320115

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 3.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 4.  Treatment of dys-immune neuropathies.

Authors:  Eduardo Nobile-Orazio
Journal:  J Neurol       Date:  2005-04       Impact factor: 4.849

Review 5.  IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results.

Authors:  Eduardo Nobile-Orazio; Fabrizia Terenghi
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 6.  Plasma exchange for Guillain-Barré syndrome.

Authors:  Sylvie Chevret; Richard Ac Hughes; Djillali Annane
Journal:  Cochrane Database Syst Rev       Date:  2017-02-27

Review 7.  Initial and long-term management of autoimmune neuropathies.

Authors:  Carol Lee Koski
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Advances in the management of Guillain-Barré syndrome.

Authors:  Deborah M Green
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

9.  Inpatient management of guillain-barré syndrome.

Authors:  Matthew Harms
Journal:  Neurohospitalist       Date:  2011-04

Review 10.  Guillain-Barré syndrome: epidemiology, pathophysiology and management.

Authors:  Satoshi Kuwabara
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.